Are We Overlooking the Most Effective Regenerative Therapy for Musculoskeletal Conditions?
- kparmstrong1
- 5 days ago
- 1 min read
PRP seems to dominate conversations on LinkedIn. It’s familiar, accessible, and widely used in orthopedic practices.
But this recent systematic review published in the Journal of Clinical Medicine analyzed 59 clinical trials and found something worth pausing over:
Unless I am reading this wrong, mesenchymal stem cell (MSC) therapies consistently outperformed PRP, peptides, and biomimetic materials in both pain reduction and functional improvement—especially in early-stage osteoarthritis and cartilage repair.
Despite this, PRP remains the more commonly discussed option.
Why the disconnect?
Is it regulatory complexity? Higher costs? Lack of awareness? Or is there a default to convenience over clinical effectiveness?
Let’s hear your perspective. Are MSCs getting the attention they deserve—or are they still waiting for their moment?
